Clinical Trials Logo

Rhinitis, Allergic, Perennial clinical trials

View clinical trials related to Rhinitis, Allergic, Perennial.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06180083 Completed - Clinical trials for Seasonal Allergic Rhinitis

Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray

Start date: March 24, 2023
Phase: Phase 1
Study type: Interventional

Single dose (four sprays) bioequivalence study of Azelastine Hydrochloride/ Fluticasone Propionate 137 microgram/50 microgram Nasal Spray and 'DYMISTA' (Azelastine Hydrochloride/Fluticasone Propionate) Nasal Spray 137 microgram/50 microgram in healthy adult human subjects.

NCT ID: NCT06051786 Completed - Allergic Rhinitis Clinical Trials

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis

Start date: August 20, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Azelastine HCl-Fluticasone propionate Nasal Spray 137-50 mcg/spray compared to Dymista™ in patients with perennial allergic rhinitis

NCT ID: NCT05122143 Completed - Clinical trials for Perennial Allergic Rhinitis

Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers

Start date: November 10, 2021
Phase: N/A
Study type: Interventional

Alleviation of allergic symptoms induced by house dust mites when using the medical device AM-301. This clinical investigation explores the efficacy and safety of AM-301 when used to reduce symptoms of house dust mite sufferers. The primary objective is to compare the efficacy of AM-301 Device between treated and non-treated subjects in the treatment of perennial allergic rhinitis (PAR).

NCT ID: NCT04654702 Completed - Asthma Clinical Trials

Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.

Start date: November 17, 2017
Phase:
Study type: Observational

Investigator examines the past prescription patterns and the reasons for the change of prescription to Monterizine capsules for Perennial Allergic Rhinitis patients with Asthma who will be taking Monterizine capsules to treat allergic rhinitis. After being given Monterizine capsules, Investigator evaluates the therapeutic effectiveness and safety for 3 months (or 6 months).

NCT ID: NCT04388358 Completed - Allergic Rhinitis Clinical Trials

Traditional Chinese Medicine for the Treatment of Perennial Allergic Rhinitis on Gut Microbiota and Immune-modulation

Start date: September 3, 2019
Phase: N/A
Study type: Interventional

40 allergic rhinitis patients in the acute phase will be enrolled in the study. All the allergic patients should be confirmed those who are over 20 years old and hypersensitive to house dust mite allergens confirmed by MAST test before study. All patients were treated with mixed formula of Chinese medicine for one months.

NCT ID: NCT04332978 Completed - Clinical trials for Perennial Allergic Rhinitis

Topical Nasal Fluticasone Propionate in the Control of Allergic Rhinitis SymptomsPerene

LB1108
Start date: July 4, 2014
Phase: Phase 3
Study type: Interventional

Phase III Study to Demonstrate the non inferiority of PLURAIR® branded nasal topical Fluticasone Propionate (FP) in relation to the FLIXONASE® brand reference drug in the control of nasal symptoms related to perennial allergic rhinitis.

NCT ID: NCT04324918 Completed - Clinical trials for Perennial Allergic Rhinitis

Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis

Start date: October 23, 2018
Phase: Phase 3
Study type: Interventional

Efficacy and safety of HCP1102 in patients with perennial allergic rhinitis : A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial

NCT ID: NCT03655210 Completed - Clinical trials for Perennial Allergic Rhinitis

To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients

Start date: February 7, 2017
Phase: Phase 3
Study type: Interventional

4week, a Multicenter, Randomized, Double-blinded, Parallel, Therapeutic confirmatory Clinical Trial

NCT ID: NCT03360071 Completed - Allergic Rhinitis Clinical Trials

A Novel Biologic Therapy for Perennial Allergic Rhinitis

Start date: December 19, 2016
Phase: Phase 2
Study type: Interventional

This is a randomized, parallel-group, double-blind, phase 2, single center, proof-of-concept study which will evaluate the effect of a preparation of FDA approved allergens (PMA) used as a sub-cutaneously administered immunotherapy for the management of allergic rhinitis (perennial and seasonal).

NCT ID: NCT03317015 Completed - Rhinitis Allergic Clinical Trials

A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)

NASANIF
Start date: November 30, 2016
Phase: Phase 3
Study type: Interventional

Primary Objective: - To assess efficacy of Nasacort® (triamcinolone) nasal spray, 55 µg per dose, in comparison with Flixonase® (fluticasone) nasal spray, 50 µg per dose, by reflective total nasal symptom score (rTNSS) (24 h) after 28 days of treatment compared with baseline (0 day of treatment) in adult patients suffering from PAR (perennial allergic rhinitis). Secondary Objectives: - To evaluate safety of Nasacort® (triamcinolone) nasal spray, in comparison with Flixonase® (fluticasone) administered for 28 days by assessment of adverse events reports. - To evaluate patient and physician satisfaction after 28 days of treatment by 5-point scale. - To estimate improvement of quality of life during the study by mini Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ).